Aromatase catalyzes the conversion of testosterone to estradiol and is involved in the physiological effects of sex hormones on brain function. Animal experiments have shown that the aromatase inhibitor, letrozole, can induce anxiety in young ovariectomized females that are used as a model of aging. Whether or not these effects would be similar in intact middle-aged animals is unknown. The aim of our study was to analyze the effects of letrozole on anxiety in middle-aged rats of both sexes. Fifteen month old male and female rats were treated daily with either letrozole or vehicle for 2 weeks. The elevated plus maze was used to test anxiety-like behaviour. Sex differences were found not only in plasma concentrations of testosterone but also in the effects of letrozole treatment on plasma testosterone (P<.05). The interaction between sex and treatment was also proven in locomotor activity (P<.05) and time spent in the open arms of the elevated plus maze (P<.05). Letrozole-treated male rats spent 95% less time in the open arms of the elevated plus maze than the control rats did (P<.05) suggesting an anxiogenic effect of aromatase inhibition. This difference was not found between letrozole-treated and vehicle-treated females. In contrast to previous experiments on young animals, letrozole seems to induce anxiety in male but not in female middle-aged rats. This sex-specific effect might be related to sex differences of oestrogen and androgen signalling in aging brains. These results should be taken into account in clinical applications of letrozole, especially in men.
Summary
Aromatase catalyzes the conversion of testosterone to estradiol and is involved in the physiological effects of sex hormones on brain function. Animal experiments have shown that the aromatase inhibitor, letrozole, can induce anxiety in young ovariectomized females that are used as a model of aging. Whether or not these effects would be similar in intact middle-aged animals is unknown. The aim of our study was to analyze the effects of letrozole on anxiety in middle-aged rats of both sexes. Fifteen month old male and female rats were treated daily with either letrozole or vehicle for 2 weeks. The elevated plus maze was used to test anxiety-like behaviour. Sex differences were found not only in plasma concentrations of testosterone but also in the effects of letrozole treatment on plasma testosterone (P<.05). The interaction between sex and treatment was also proven in locomotor activity (P<.05) and time spent in the open arms of the elevated plus maze (P<.05). Letrozole-treated male rats spent 95% less time in the open arms of the elevated plus maze than the control rats did (P<.05)
suggesting an anxiogenic effect of aromatase inhibition. This difference was not found between letrozole-treated and vehicle-treated females. In contrast to previous experiments on young animals, letrozole seems to induce anxiety in male but not in female middle-aged rats. This sex-specific effect might be related to sex differences of oestrogen and androgen signalling in aging brains. These results should be taken into account in clinical applications of letrozole, especially in men.
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| INTRODUCTION
Aromatase inhibition is an effective adjuvant treatment for hormonedependent breast cancer, especially in postmenopausal women. 1, 2 Drugs inhibiting aromatase activity, block the conversion of estradiol from its precursor, testosterone.
3 This mechanism is different from the widely used oestrogen receptor blocker/modulator, tamoxifen.
4
Letrozole is a non-steroid aromatase inhibitor that was shown to be superior to tamoxifen as an initial therapy and a neoadjuvant treatment in various stages of breast cancer.
5
Beyond their clear indication in the treatment of breast cancer, aromatase inhibitors might be useful for men in the treatment of infertility 6 or gynecomastia induced during testosterone supplementation. 7 One of the potential applications of aromatase inhibitors in men might be the treatment of hypogonadism, providing an alternative to testosterone supplementation, which leads to numerous clinically relevant side effects including erythrocytosis and hyperestrogenism. 8, 9 Unlike testosterone supplementation, aromatase inhibitor treatment preserves fertility. However, this is only a consequence of the lack of negative feedback on the pituitary gland and its production of gonadotropins, which is inhibited by exogenous testosterone.
10
The increasing number of applications of aromatase inhibitors makes the research on their potential side effects clinically important. The known adverse effects of aromatase inhibitor treatment are limited to mainly skeletal and musculoskeletal complications.
11
Aromatase is not a tumour marker and has specific physiological func- Recently, it has been demonstrated that the administration of the aromatase inhibitor, fadrozole, leads to fear generalization in the passive avoidance chamber in male rats. 21 All of these experiments have one thing in common-they were conducted on young adult animals.
Patients receiving aromatase inhibitors include, primarily, postmenopausal women and elderly men with hypogonadism. It is known that local estradiol synthesis, as well as oestrogen signalling in the brain, change during aging. 22, 23 Thus, it is likely that a young brain will respond differently to the inhibition of estradiol synthesis when compared to an older brain. Therefore, experimental research attempting to mirror the effect of therapy mainly used in advanced age patients should be conducted on older, rather than younger, animals to be more clinically relevant.
The aim of our study was to examine whether or not letrozole treatment administered to middle-aged rats of both sexes affects anxiety-like behaviour. In addition, we hypothesized that the potential effects might be sex-specific.
| RESULTS
Testosterone concentrations in plasma differed between the groups In male rats, the difference between vehicle-treated and letrozole- 
| DISCUSSION
The results of our study showed that letrozole has sex-specific effects on testosterone as well as on anxiety-like behaviour. Letrozole treatment abolished sex differences in plasma testosterone. In female rats treated with the aromatase inhibitor, plasma testosterone was higher;
however, in male rats, plasma testosterone was lower than in the particular control groups. Locomotor activity in the elevated plus maze was higher in female rats but was unaffected by letrozole in either sex. The variability of the number of entries to the open arms was very high across all groups, and no effect of sex or treatment was observed.
The main finding of this experiment is that letrozole affects time spent in the open arms of the elevated plus maze test in a sex-specific manner. While letrozole induced an anxiogenic effect in male rats, indicated by a shorter time spent in the open arms, it had no significant effect on anxiety-like behaviour in female rats.
As both the number of patients receiving aromatase inhibitors and the duration of the treatment gradually rise, studying the potential neurocognitive side effects, no matter how subtle they might be, becomes increasingly more relevant. 24 Anxiety induced by letrozole in male rats might be caused by decreased oestrogen signalling in specific brain areas, but it may also be caused by increased androgen signalling due to the potentially higher local testosterone concentrations.
Systemic plasma testosterone, however, was unaffected by 2 weeks of letrozole treatment in male rats. From clinical observations, it is known that letrozole and other aromatase inhibitors stimulate the production of gonadotropins in the pituitary gland. 25 Some of the side effects, including anxiety, might arise from the likely higher luteinizing hormone secretion.
26
Sex-specific effects on anxiety could be caused by sex differences in oestrogen signalling in the brain. 27 Oestrogen receptor agonists had no effect on anxiety in male rats in contrast to their anxiolytic effects in female rats. [28] [29] [30] However, this lack of effect of exogenous estrogens does not mean that inhibiting the synthesis of endogenous estradiol will not have an effect either, especially in middle-aged animals. In our previous study in young adult rats, we showed that testosterone has an anxiolytic effect and that it is mediated, at least partly, by the androgen receptor. 31 Testosterone is not only a male hormone, but it is also a precursor of dihydrotestosterone and estradiol. 13 Many studies suggest that the anxiolytic effect of testosterone can be mediated through its 5α-reduced 30,32-34 as well as aromatized metabolites. 35, 36 What happens with the experimentally administered testosterone in the particular brain areas is likely context-dependent, and the context includes age.
Aromatase knock-out mice are a useful tool for studying the role of aromatase in brain physiology. Phenotyping of these mice showed altered sociosexual behaviour and spatial memory. 37, 38 Interestingly, in one study, aromatase knock-out mice presented comparable behaviour to wild type mice. 39 This analysis included anxiety-like behaviour that was tested using the elevated plus maze. However, similar to other relevant published experiments, 19-21 the mice were tested at the age of 10 weeks as young adults. This might explain the different outcomes found in our experiment conducted on middle-aged animals. Aging is associated with changes in local estradiol synthesis and signalling.
22
Although this has not been analyzed in our study, it is likely an important factor influencing the effects of aromatase inhibition.
The main limitation of our study is that we have analyzed anxiety-like behaviour at a single time point. Repeated testing in the elevated plus maze might influence the outcome. 40 A larger dynamic study with several groups, each tested at a different age, could be more informative. The high variability observed in behavioural measures is of biological rather than technical nature. However, based on our data we can only suggest its source, which might be related to the age of the animals and age-associated cognitive and metabolic changes that were not analyzed in the current study. One of the numerous other sources of bias might be the oestrous cycle in female rats. However, given the age of the animals and the lack of sex differences in the variance of the observed behavioural measures, the oestrous cycle is unlikely to be a major source of their variability. Similar experiments in genetic models might uncover the details of the molecular mechanisms of the observed effects in middle-aged animals.
In conclusion, our experiment has shown that letrozole induces anxiety in middle-aged male rats but not in middle-aged female rats.
To the best of our knowledge, this is the first experiment analyzing the behaviour of middle-aged animals treated with an aromatase inhibitor, which confirms clinical studies showing subtle or no effects of letrozole on brain functions in women. Furthermore, these results should be taken into account in the context of the recent efforts to establish letrozole as a treatment approach for hypogonadism in elderly men.
41,42
4 | METHODS
| Ethical statement
All procedures were conducted in accordance with Slovak legislation and were approved by the Ethics committee of the Institute of Molecular Biomedicine, Comenius University, Bratislava.
| Animals
In this study, Lewis rats (n=46) were used. Young (4-8 weeks old) female and male Lewis rats were obtained from a commercial breeding colony (Anlab, Prague, Czech Republic). The rats were group-housed (3-5 per cage) throughout the study in polycarbonate cages (50×36×19 cm). Animals were kept in a temperature-(22±2°C) and humidity-controlled room (55±10%) with 12:12 hour light/dark cycle. Rats had ad libitum access to food and water.
| Treatment
Middle-aged animals (15 months old) were treated for 14 days with a daily subcutaneous injection of either letrozole, at a dose of 1 mg/kg (LET; Letrozole L6545, Sigma-Aldrich Chemie, Darmstadt, Germany)
or an olive oil vehicle (CTRL; Olivae Oleum Raffinatum, Galvex, Banská Bystrica, Slovak Republic). The dose of the letrozole treatment was chosen according to previously published data. [43] [44] [45] Rats were divided into groups according to sex and randomized to the applied treatment:
males and females receiving vehicle (males CTRL, n=14; females CTRL, n=10) or letrozole (males LET, n=12; females LET, n=10).
| Elevated plus maze
One day after the last injection, the elevated plus maze test was performed. The elevated plus maze apparatus (elevated 50 cm above the floor) consisted of two open arms (45 cm×10 cm), two closed arms (45×10×40 cm) and a central platform (10 cm×10 cm).
Testing of animals was conducted between 08.00 and 09.00 hours during the active phase of the rats in a slightly lit room using auto- 
| Testosterone measurement
On the day of behavioural testing, the animals were killed by (<0.1%), estrone (<0.1%), and danazol (<0.1%). The analytical sensitivity was 0.083 ng/mL. The average intra-assay coefficient of variation for this testosterone assay was below 5%, and the inter-assay coefficient of variation was below 10%.
| Statistical analysis
The data were analyzed using the GraphPad Prism 6 software (GraphPad; La Jolla, CA, USA). The two-way ANOVA was chosen for the statistical evaluation of the outcomes with the factors sex, treatment and their interaction. For potential post hoc analyses of grouprelated variability, the Sidak test was used. P values less than 0.05 were considered significant. Results are presented as mean + standard error of the mean.
